Letter to the Editor
Sir: Donepezil, a centrally acting acetylcholinesterase inhibitor, is the first drug introduced in Japan for the symptomatic relief of cognitive impairment in patients with mildto- moderate Alzheimer’s disease. Some authors suggest that cholinomimetic treatment may also benefit certain behavioral problems associated with Alzheimer’s disease such as apathy, psychotic symptoms, and agitation. However, several adverse events related to donepezil have been reported so far, the most common being gastrointestinal disturbances due to cholinomimetic effects of donepezil.
Author Affiliations
Save
Share
Cite
